CA2448438A1 - Soft elastic capsules comprising ritonavir and/or lopinavir - Google Patents

Soft elastic capsules comprising ritonavir and/or lopinavir Download PDF

Info

Publication number
CA2448438A1
CA2448438A1 CA002448438A CA2448438A CA2448438A1 CA 2448438 A1 CA2448438 A1 CA 2448438A1 CA 002448438 A CA002448438 A CA 002448438A CA 2448438 A CA2448438 A CA 2448438A CA 2448438 A1 CA2448438 A1 CA 2448438A1
Authority
CA
Canada
Prior art keywords
fill
shell
soft elastic
weight
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002448438A
Other languages
English (en)
French (fr)
Inventor
Sergio Petriconi
Alessandro Barbato
Roberta Scuppa
Azita Saleki-Gerhardt
Martin Urch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2448438A1 publication Critical patent/CA2448438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002448438A 2001-05-25 2002-05-21 Soft elastic capsules comprising ritonavir and/or lopinavir Abandoned CA2448438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86628501A 2001-05-25 2001-05-25
US09/866,285 2001-05-25
PCT/US2002/015955 WO2002096395A1 (en) 2001-05-25 2002-05-21 Soft elastic capsules comprising ritonavir and/or lopinavir

Publications (1)

Publication Number Publication Date
CA2448438A1 true CA2448438A1 (en) 2002-12-05

Family

ID=25347294

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002448438A Abandoned CA2448438A1 (en) 2001-05-25 2002-05-21 Soft elastic capsules comprising ritonavir and/or lopinavir

Country Status (8)

Country Link
EP (1) EP1395249A1 (ja)
JP (1) JP2005508294A (ja)
AR (1) AR034995A1 (ja)
CA (1) CA2448438A1 (ja)
MX (1) MXPA03010771A (ja)
PE (1) PE20030098A1 (ja)
UY (1) UY27306A1 (ja)
WO (1) WO2002096395A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329579T1 (de) 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
KR20150021510A (ko) 2012-05-03 2015-03-02 시플라 리미티드 항레트로바이러스 조성물
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201917252D0 (en) 2019-11-27 2020-01-08 Pharmaceutic compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
PT1183026E (pt) * 1999-06-04 2006-11-30 Abbott Lab Formulações farmacêuticas melhoradas incluindo ritonavir
US6608198B2 (en) * 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical

Also Published As

Publication number Publication date
JP2005508294A (ja) 2005-03-31
UY27306A1 (es) 2002-12-31
MXPA03010771A (es) 2004-07-01
EP1395249A1 (en) 2004-03-10
AR034995A1 (es) 2004-04-14
PE20030098A1 (es) 2003-02-12
WO2002096395A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
JP4523799B2 (ja) 医薬組成物
US6232333B1 (en) Pharmaceutical composition
US7141593B1 (en) Pharmaceutical formulations
EP1733725B1 (en) Farmaceutical formulations comprising at least one HIV protease inhibiting compound
US20030138483A1 (en) Soft elastic capsules and compositions thereof
CA2448438A1 (en) Soft elastic capsules comprising ritonavir and/or lopinavir
EP2269591B1 (en) Improved pharmaceutical formulations

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued